secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001683168-24-005145
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma boosts ATM equity facility from $5.2M to $30.2M; $5.19M already sold
-------------------------------------------------------------------------------

- On July 30, 2024, CNS Pharmaceuticals increased the aggregate sales price under its ATM agreement to $25M, for a total of $30.2M including original $5.2M.
- As of July 30, 2024, the Company sold 7,206,743 shares for gross proceeds of approximately $5.19 million.
- Outstanding shares as of July 30, 2024: 10,075,017; remaining capacity implies significant potential dilution.
- Sales are conducted through A.G.P./Alliance Global Partners under an effective S-3 shelf registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824005145/0001683168-24-005145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824005145/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer